The value of referring to recently introduced antipsychotics as "second generation"

被引:13
作者
Lohr, JB [1 ]
Braff, DL [1 ]
机构
[1] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA
关键词
D O I
10.1176/appi.ajp.160.8.1371
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
引用
收藏
页码:1371 / 1372
页数:2
相关论文
共 8 条
[1]   Tardive dyskinesia and atypical antipsychotic drugs [J].
Casey, DE .
SCHIZOPHRENIA RESEARCH, 1999, 35 :S61-S66
[2]   Current and emerging second-generation triptans in acute migraine therapy: A comparative review [J].
Deleu, D ;
Hanssens, Y .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (07) :687-700
[3]  
Feltus M S, 1999, Can J Clin Pharmacol, V6, P187
[4]   Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? [J].
Green, MF ;
Kern, RS ;
Braff, DL ;
Mintz, J .
SCHIZOPHRENIA BULLETIN, 2000, 26 (01) :119-136
[5]   Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications [J].
Green, MF ;
Braff, DL .
BIOLOGICAL PSYCHIATRY, 2001, 49 (04) :374-384
[6]   THE EVOLUTION OF THE SEROTONIN-DOPAMINE ANTAGONIST CONCEPT [J].
HUTTUNEN, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (01) :S4-S10
[7]  
Möller HJ, 1999, EUR ARCH PSY CLIN N, V249, P99
[8]   Risperidone versus clozapine in treatment-resistant schizophrenia:: A randomized pilot study [J].
Wahlbeck, K ;
Cheine, M ;
Tuisku, K ;
Ahokas, A ;
Joffe, G ;
Rimón, R .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2000, 24 (06) :911-922